Litcius/Paper detail

Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo

Andressa Chequin, Luiz E. Costa, Felipe F. de Campos, Angie D.B. Moncada, Lucas Trevisan França de Lima, Lucas R. Sledz, Guilherme F. Picheth, Eliana Rezende Adami, Alexandra Acco, Marcos Brown Gonçalves, Graciele C. M. Manica, Gláucio Valdameri, Lúcia de Noronha, José Ederaldo Queiroz Telles, Elisa Helena Farias Jandrey, Érico T. Costa, Fabrício F. Costa, Emanuel Maltempi de Souza, Edneia A. S. Ramos, Giseli Klassen

2021Chemico-Biological Interactions35 citationsDOIOpen Access PDF

Topics & Concepts

LiraglutideCDH1In vivoDNMT1DNA methylationGene knockdownPharmacologyCancerCancer researchChemistryBiologyGene expressionMedicineEndocrinologyInternal medicineApoptosisBiochemistryCellGeneType 2 diabetesDiabetes mellitusGeneticsCadherinEpigenetics and DNA MethylationMetabolism, Diabetes, and CancerHistone Deacetylase Inhibitors Research
Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo | Litcius